Assessing effectiveness of Weight loss and Exercise programs for older adults with Sarcopenic Obesity delivered via MobilE application/s

Not Applicable

Recruiting

• Conditions: Sarcopenic Obesity; Musculoskeletal - Other muscular and skeletal disorders; Diet and Nutrition - Obesity

• Registration Number: ACTRN12621000236897
• Lead Sponsor: Deakin University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-03-05
• Last Update Posted: 13 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 116

Inclusion Criteria

Prospective participants must be aged 60-89 years; English-speaking; have a body mass index greater than or equal to 30 kg/m2, score 2 greater than or equal to on the SARC-F questionnaire, able to walk across a room unaided; with access to a smartphone connected to an internet network; willing to complete a 24-week weight loss intervention and also be willing to participate should they be randomised to either intervention arm.

Exclusion Criteria

Participants are ineligible if they currently reside in a nursing home; are unable to walk across a room are non-English speaking or have difficulty communicating with study personnel due to speech or hearing problems; report less than or equal to 4 weeks self-reported participation in a supervised exercise or dietary program targeted at weight loss or strength gains in the past six months; taking any medication or supplements that facilitate weight loss; are planning to be away from home for less than or equal to 4 weeks during the intervention; and self-reported diagnosis of: progressive neurological disorders including Parkinson’s Disease and multiple sclerosis; schizophrenia or bipolar disorder; severe knee or hip osteoarthritis (awaiting or have had a joint replacement) that would interfere with ability to complete functional exercise and tests; cardiovascular disease (including NYHA Class III or IV congestive heart failure, clinically significant valvular disease, history of cardiac arrest, presence of an implantable cardiac defibrillator, or uncontrolled angina); lung disease requiring regular use of corticosteroids or supplemental oxygen; renal disease requiring dialysis; hyper- or hypothyroidism that would interfere with the weight loss program; and any other disorder of such severity that life expectancy is less than 12 months. or any cognitive or physical impairment or disability that in the opinion of the participant’s’ GP/specialist and/or study investigators would result in the participant having difficulty interacting with the Physitrack application or performing unsupervised exercise safely. Finally, participants must answer ‘no’ to all six questions on the Exercise and Sports Science Australia (ESSA) pre-exercise screening tool to ensure that it is safe for them to exercise at moderate exertion. This is a validated and recommended pre-exercise screening tool endorsed by Australia’s peak exercise body (ESSA).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in Muscular Power (Vertical Jump (W/kg) as assessed by a Leonardo Mechanography Ground Reaction Force Platform[Baseline, follow-up (24 weeks post-intervention commencement)]